Veeva Systems (VEEV) ended the recent trading session at $203.14, demonstrating a -0.15% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 1.03%. Elsewhere, the Dow saw an upswing of 0.46%, while the tech-heavy Nasdaq appreciated by 1.19%. The the stock of provider of cloud-based software services for the life sciences industry has fallen by 5.25% in the past month, lagging the Computer and Technology sector's loss of 0.68% and the S&P 500's loss of ...

In the latest market close, Veeva Systems (VEEV) reached $201.58, with a +0.33% movement compared to the previous day. This move outpaced the S&P 500's daily gain of 0.32%. At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.35%. Heading into today, shares of the provider of cloud-based software services for the life sciences industry had lost 13.29% over the past month, lagging the Computer and Technology sector's loss of 1.9% and the S&P 500's loss of 2% in that time. Investors will ...

Veeva Systems (VEEV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this provider of cloud-based software services for the life sciences industry have returned -14.1% over the past month versus the Zacks S&P 500 composite's -3.2% change. The Zacks Internet - Software industry, to which Veeva belongs, has lost 9.4% over this period. Now the key question is: Where could the s ...

Veeva Systems (VEEV) recently announced that the Veeva AI Partner Program is likely to provide partners with the cutting-edge tools and assistance required to smoothly combine Generative AI (GenAI) solutions with Veeva Vault applications. For GenAI applications to provide value, they require rapid, secure, and accurate data access. This is made feasible by the Vault Platform and Vault Direct Data API, which provide data access significantly quicker than conventional response APIs. Price Performance Over the ...

The latest trading session saw Veeva Systems (VEEV) ending at $201.10, denoting a +1.02% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 1.2%. Meanwhile, the Dow experienced a rise of 0.69%, and the technology-dominated Nasdaq saw an increase of 1.59%. Coming into today, shares of the provider of cloud-based software services for the life sciences industry had lost 13.23% in the past month. In that same time, the Computer and Technology sector lost 6.83%, w ...

Veeva Crossix helps 16 of the top 20 biopharmas more efficiently reach clinically relevant patients PLEASANTON, Calif., April 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 16 of the top 20 biopharmas are increasing media efficiency with Veeva Crossix Prime Segments, privacy-safe data helping life sciences brands reach highly-qualified health audiences. Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qual ...

Veeva AI Partner Program - Veeva Systems宣布推出Veeva AI Partner Program，为合作伙伴提供先进技术和支持，以便将生成式人工智能（GenAI）解决方案与Veeva Vault应用程序无缝集成[1] - Veeva AI Partner Program包括Vault Direct Data API培训和支持，以建立对Veeva Vault平台独特、高速API的专业知识。这种新型API使Vault数据可在比传统API快100倍的速度访问，并且在大型数据集上具有事务性和一致性[2] - Veeva AI Partner Program是Veeva专注于为生命科学行业提供人工智能的战略的一部分。Vault Direct Data API和AI合作伙伴计划使客户和合作伙伴更容易构建与Vault应用程序无缝集成的人工智能应用程序[4]

Veeva Systems财务表现 - Veeva Systems在2024财年的营收增长为9.7%，超出分析师预期的7.3%[2] - Veeva的总地址able市场（TAM）为200亿美元，仅有12%的渗透率，未来几年TAM可能会扩大[16] - 根据折现现金流（DCF）方法，Veeva的内在价值可能达到每股286美元，主要受益于过去6年FCF边际的增长[25][26][31][33] Veeva的商业模式和发展策略 - Veeva的商业模式展现出了弹性，即使在与美联储政策和客户对未来的悲观看法相关的不确定性情况下也能保持稳健[3] - 研发解决方案是未来增长的关键因素，结合Veeva Vault CRM迁移[5] - Veeva正在积极推进向Veeva Vault CRM的迁移计划，已有三家前20家制药公司完成迁移[9] Veeva与IQVIA的竞争和诉讼 - Veeva与IQVIA之间的诉讼可能存在风险，但预计无论结果如何，都不会对Veeva的增长前景产生重大影响[34] - Veeva采取更开放的方式处理与IQVIA的诉讼问题，提供给IQVIA获取Veeva产品的可能性[35] - Veeva的财务指标远远优于IQVIA，包括过去5年的FCF利润率和收入增长，Veeva的FCF利润率平均超过30%，年收入增长率在10%至30%之间[37]

Keynote speakers include leaders from Bayer, Genentech, Novo Nordisk, and Takeda sharing strategies for effective commercialization and engagement PLEASANTON, Calif., April 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston. Commercial and medical affairs professionals will share how they are innovating across content, data and analyt ...

产品介绍 - Veeva Systems推出Veeva Vault CRM Campaign Manager，简化并加速向医疗专业人士进行非个人推广[1] - Vault CRM Campaign Manager与Veeva Vault CRM同处一个Vault中，并共享相同的客户数据，为真正的客户中心性提供了无缝同步[1] 功能特点 - 用户可以定义一组活动，如电子邮件或短信，并将共享资产附加到活动中，所有活动都与活动相关联以确保合规性和分析[2] - 用户可以手动或动态创建客户段和目标列表，目标列表可以与多个活动关联，并可发布供现场协作使用[2] - 大规模电子邮件功能与现场团队紧密集成，使现场团队能够立即查看和控制发送给关键联系人的电子邮件，以增加客户中心性[3] 创新亮点 - 简单的拖放工具可创建所有内容类型，包括落地页、消息模板、电子邮件模板和片段，客户可以根据需要进行自定义[6] - Vault CRM Campaign Manager的推出是将销售和营销团队汇聚在一起实现客户中心性的又一步[7]